EVAX (Evaxion AS) EBITDA Margin %: 0.00% (As of Mar. 2026)

What is Evaxion AS EBITDA Margin %?

Evaxion AS EVAX -1.59% 22 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates EVAX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 944 Biotechnology companies, Evaxion AS ranks worse than 57.2% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Evaxion AS's EBITDA for the three months ended in Mar. 2026 was $-3.51 Mil. Evaxion AS's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Evaxion AS's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Evaxion AS (NAS:EVAX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Evaxion AS EBITDA Margin % Related Terms

Evaxion AS EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Evaxion AS's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evaxion AS EBITDA Margin % Chart

Evaxion AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

0.00

-29,319.18

-292.64

-94.63

Evaxion AS Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															0.00	-12,932.43	76.24	0.00	0.00

EVAX vs DARE, LITS, TVGN: EBITDA Margin % Comparison

For the Biotechnology subindustry, Evaxion AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evaxion AS EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion AS's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Evaxion AS's EBITDA Margin % falls into.

Save Embed

22GF Score

Evaxion AS EVAX

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Evaxion AS EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Evaxion AS's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-7.124	/	7.528
	=	-94.63 %

Evaxion AS's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-3.513	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Evaxion AS (EVAX) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evaxion AS and its competitors. According to the industry distribution chart, Evaxion AS ranks #540 out of 944 companies in the Biotechnology industry, placing it in the top 57.2%.

Is Evaxion AS's EBITDA Margin % too high?

Evaxion AS's current EBITDA Margin % is 0.00%. Based on the distribution chart, Evaxion AS ranks #540 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Evaxion AS has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.

How does Evaxion AS's EBITDA Margin % compare to DARE and LITS?

According to the Biotechnology industry distribution chart, Evaxion AS ranks #540 out of 944 companies for EBITDA Margin %. This places Evaxion AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evaxion AS and its competitors. Evaxion AS's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Evaxion AS stock overvalued right now?

Evaxion AS (EVAX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Evaxion AS's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Evaxion AS (EVAX), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evaxion AS Business Description

Industry Healthcare Biotechnology

Comparable Companies DARE LITS TVGN BOLD ALGS PLRZ TVRD ABVC APLM GRDX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address Dr. Neergaards Vej 5f, Horsholm, DNK, 2970

Website https://www.evaxion.ai

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

22GF Score

Get the complete analysis for EVAX

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.23

Price

View EVAX Analysis

See EBITDA Margin % data for all stocks →